Dark

Check out our Dark Pool Levels

QNRX
Quoin Pharmaceuticals, Ltd.
stock NASDAQ ADR

At Close

Aug 28, 2026 3:59:47 PM EDT

6.13USD+18.914%(+0.98)31,016,956

0.00Bid 0.00Ask 0.00Spread

Pre-market

Aug 28, 2026 9:29:59 AM EDT

7.26USD+40.834%(+2.11)2,001,623

After-hours

Aug 28, 2026 4:59:30 PM EDT

5.88USD-4.078%(-0.25)83,229

OverviewHistoricalExchangesShortsNews

Jan 29, 2022

07:11AM EST QNRX: Laying the Groundwork to Launch Multiple Treatments for Rare & Orphan Diseases Benzinga

Jan 26, 2022

08:07AM EST Quoin Pharmaceuticals Signs Exclusive Distribution Agreement With OrphanDC For Its Lead Asset, QRX003, For Netherton Syndrome Benzinga

08:00AM EST -OrphanDC Gains Exclusive Rights to Commercialize QRX003 in Key Countries in Latin America- Fourth Distribution Partnership Established Since Going Public in October 2021- Additional Territories in Discussion GlobeNewswire Inc

Jan 7, 2022

01:07PM EST Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022 Benzinga

01:05PM EST Maxim Group Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $5 Benzinga

Dec 15, 2021

10:05AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021 Benzinga

09:04AM EST Quoin Pharma Reports Exclusive Distribution Deal With Orpharm For QRX003 For Netherton Syndrome, No Terms Disclosed Benzinga

09:00AM EST Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with GlobeNewswire Inc

06:25AM EST JMP Securities Initiates Coverage On Quoin Pharmaceuticals with Market Outperform Rating, Announces Price Target of $8 Benzinga

Nov 11, 2021

10:19AM EST Mid-Morning Market Update: Markets Mixed; Tapestry Earnings Beat Estimates Benzinga

08:33AM EST Quoin Pharmaceuticals, Genpharm Services Sign Exclusive License, Distribution Agreement For Quoin's Lead Asset, QRX003; Terms Not Disclosed Benzinga

08:30AM EST Quoin Pharmaceuticals and Genpharm Services Sign Exclusive License GlobeNewswire Inc

Nov 8, 2021

10:13AM EST Quoin, AFT Pharmaceuticals Ink Licensing Pact For Lead Candidate In Genetic Skin Disease Benzinga

08:08AM EST Quoin Pharmaceuticals Signs Exclusive Licensing And Distribution Agreement With AFT Pharmaceuticals For Its Lead Asset, QRX003 Benzinga

08:00AM EST AFT Gains Exclusive Rights to Commercialize QRX003 in Australia and New Zealand GlobeNewswire Inc

Nov 4, 2021

09:34AM EDT Quoin Pharmaceuticals Appoints Gordon Dunn As Chief Financial Officer Benzinga

Nov 2, 2021

10:58AM EDT Quoin Pharmaceuticals Announces Signing Of Exclusive License From Queensland University Of Technology, Australia Benzinga

08:30AM EDT Quoin Pharmaceuticals Announces Signing of Exclusive License from GlobeNewswire Inc

Share